{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:25:06Z","timestamp":1793993106571,"version":"4.8.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T (CAR-T) therapy yield remarkable responses in patients with relapsed\/refractory multiple myeloma (R\/RMM). Circulating tumor DNA (ctDNA) reportedly exhibits distinct advantages in addressing the challenges posed by tumor heterogeneity in the distribution and genetic variations in R\/RMM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Herein, the ctDNA of 108 peripheral blood plasma samples from patients with R\/RMM at the First Affiliated Hospital, School of Medicine, Zhejiang University was thoroughly investigated before administration of anti-BCMA CAR-T therapy to establish its predictive potential. Flow cytometry is used primarily to detect subgroups of T cells or CAR-T cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In this study, several tumor and T cell effector-mediated factors were considered to be related to treatment failure by an integrat analysis, including higher percentages of multiple myeloma (MM) cells in the bone marrow (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.0125), lower percentages of CAR-T cells in the peripheral blood at peak (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.0375), and higher percentages of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.0340). Furthermore, there is a substantial correlation between high ctDNA level (&gt;143\u00a0ng\/mL) and shorter progression-free survival (PFS) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.007). Multivariate Cox regression analysis showed that high levels of ctDNA (&gt;143\u00a0ng\/mL), MM-driven high-risk mutations (including\n                      <jats:italic toggle=\"yes\">IGLL5<\/jats:italic>\n                      [\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.004],\n                      <jats:italic toggle=\"yes\">IRF4<\/jats:italic>\n                      [\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.024], and\n                      <jats:italic toggle=\"yes\">CREBBP<\/jats:italic>\n                      [\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.041]), number of multisite mutations, and resistance-related mutation (\n                      <jats:italic toggle=\"yes\">ERBB4<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a00.040) were independent risk factors for PFS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Finally, a ctDNA-based risk model was built based on the above independent risk factors, which serves as an adjunct non-invasive measure of substantial tumor burden and a prognostic genetic feature that can assist in predicting the response to anti-BCMA CAR-T therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registeration:<\/jats:title>\n                    <jats:p>Chinese Clinical Trial Registry (ChiCTR2100046474) and National Clinical Trial (NCT04670055, NCT05430945).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003306","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T04:02:28Z","timestamp":1730865748000},"page":"2481-2490","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Predictive value of pre-treatment circulating tumor DNA genomic landscape in patients with relapsed\/refractory multiple myeloma undergoing anti-BCMA CAR-T therapy: Insights from tumor cells and T cells"],"prefix":"10.1097","volume":"138","author":[{"given":"Rongrong","family":"Chen","sequence":"first","affiliation":[{"name":"Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiang","family":"Jin","sequence":"additional","affiliation":[{"name":"School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Liu","sequence":"additional","affiliation":[{"name":"Hematology and Immunology Laboratory, Liangzhu Laboratory, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Yang","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingnan","family":"Xiao","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Feng","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Hong","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Fu","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhen","family":"Cui","sequence":"additional","affiliation":[{"name":"Hematology and Immunology Laboratory, Liangzhu Laboratory, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simao","family":"Huang","sequence":"additional","affiliation":[{"name":"Hematology and Immunology Laboratory, Liangzhu Laboratory, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Wei","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, China"},{"name":"School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, China"},{"name":"Hematology and Immunology Laboratory, Liangzhu Laboratory, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, China"},{"name":"School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, China"},{"name":"Hematology and Immunology Laboratory, Liangzhu Laboratory, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"R1-20260407","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20260407","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1097\/CM9.0000000000002735","article-title":"Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma","volume":"136","author":"Yan","year":"2023","journal-title":"Chin Med J"},{"key":"R3-20260407","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1749-6632.2000.tb06608.x","article-title":"The origin and mechanism of circulating DNA","volume":"906","author":"Stroun","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"R4-20260407","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.3390\/cancers14194914","article-title":"Circulating tumor DNA: Less invasive, more representative method to unveil the genomic landscape of newly diagnosed multiple myeloma than bone marrow aspirates","volume":"14","author":"Liu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R5-20260407","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1038\/s41375-019-0469-x","article-title":"Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients","volume":"33","author":"Mithraprabhu","year":"2019","journal-title":"Leukemia"},{"key":"R6-20260407","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"R7-20260407","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"R8-20260407","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/CM9.0000000000002476","article-title":"Challenges and optimal strategies of CAR T therapy for hematological malignancies","volume":"136","author":"Zhang","year":"2023","journal-title":"Chin Med J"},{"key":"R9-20260407","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"key":"R10-20260407","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"key":"R11-20260407","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"R12-20260407","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","article-title":"Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas","volume":"41","author":"Sworder","year":"2023","journal-title":"Cancer Cell"},{"key":"R13-20260407","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41408-017-0028-5","article-title":"MRD in multiple myeloma: More questions than answers?","volume":"7","author":"Moreau","year":"2017","journal-title":"Blood Cancer J"},{"key":"R14-20260407","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"key":"R15-20260407","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41467-018-04001-5","article-title":"Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma","volume":"9","author":"Manier","year":"2018","journal-title":"Nat Commun"},{"key":"R16-20260407","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1038\/s41375-018-0115-z","article-title":"Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing","volume":"32","author":"Guo","year":"2018","journal-title":"Leukemia"},{"key":"R17-20260407","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat Commun"},{"key":"R18-20260407","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: A flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"R19-20260407","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"R20-20260407","doi-asserted-by":"crossref","first-page":"8135","DOI":"10.4049\/jimmunol.180.12.8135","article-title":"CTLs directed against HER2\u00a0specifically cross-react with HER3 and HER4","volume":"180","author":"Conrad","year":"2008","journal-title":"J Immunol"},{"key":"R21-20260407","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-018-0062-y","article-title":"A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5","volume":"8","author":"White","year":"2018","journal-title":"Blood Cancer J"},{"key":"R22-20260407","doi-asserted-by":"crossref","first-page":"991091","DOI":"10.3389\/fimmu.2022.991091","article-title":"PTPRD\/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types","volume":"13","author":"Shang","year":"2022","journal-title":"Front Immunol"},{"key":"R23-20260407","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"key":"R24-20260407","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cell.2020.09.001","article-title":"Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition","volume":"183","author":"Nabet","year":"2020","journal-title":"Cell"},{"key":"R25-20260407","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41375-021-01492-y","article-title":"Cell-free DNA for the detection of emerging treatment failure in relapsed\/ refractory multiple myeloma","volume":"36","author":"Waldschmidt","year":"2022","journal-title":"Leukemia"},{"key":"R26-20260407","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"key":"R27-20260407","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"R28-20260407","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.21.00377","article-title":"Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: Results of a prospective multi-institutional trial","volume":"39","author":"Frank","year":"2021","journal-title":"J Clin Oncol"},{"key":"R29-20260407","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/jjco\/hym074","article-title":"The prolonged activated partial thromboplastin time at diagnosis indicates less favorable prognosis in IgA myeloma","volume":"37","author":"Teng","year":"2007","journal-title":"Jpn J Clin Oncol"},{"key":"R30-20260407","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3389\/fimmu.2020.02153","article-title":"Conventional treatment for multiple myeloma drives premature aging phenotypes and metabolic dysfunction in T cells","volume":"11","author":"Cooke","year":"2020","journal-title":"Front Immunol"},{"key":"R31-20260407","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1038\/s41467-022-31430-0","article-title":"The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma","volume":"13","author":"Vo","year":"2022","journal-title":"Nat Commun"},{"key":"R32-20260407","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3390\/cancers11070917","article-title":"DNA-repair gene mutations are highly prevalent in circulating tumour DNA from multiple myeloma patients","volume":"11","author":"Mithraprabhu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R33-20260407","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1158\/1078-0432.CCR-20-0951","article-title":"Early relapse risk in patients with newly diagnosed multiple myeloma characterized by next-generation sequencing","volume":"26","author":"D\u2019Agostino","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R34-20260407","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.3390\/cancers15164155","article-title":"Understanding DNA damage response and DNA repair in multiple myeloma","volume":"15","author":"Petrilla","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R35-20260407","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.leukres.2018.07.025","article-title":"IRF4 in multiple myeloma-Biology, disease and therapeutic target","volume":"72","author":"Agnarelli","year":"2018","journal-title":"Leuk Res"},{"key":"R36-20260407","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/1078-0432.CCR-19-2309","article-title":"Mutation-derived neoantigen-specific T-cell responses in multiple myeloma","volume":"26","author":"Perumal","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R37-20260407","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s13402-020-00499-4","article-title":"The role of ErbB4 in cancer","volume":"43","author":"Segers","year":"2020","journal-title":"Cell Oncol (Dordr)"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T20:00:48Z","timestamp":1775592048000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":37,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003306","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"2024-03-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}